Viral pneumonia is caused by viruses that infect the lungs’ air sacs, triggering inflammation and fluid buildup that interfere with oxygen exchange. The most common culprits are influenza, respiratory syncytial virus (RSV), rhinoviruses, and coronaviruses, though the specific virus responsible varies significantly by age. Unlike bacterial pneumonia, which often strikes a single lobe of the lung, viral pneumonia typically causes patchy inflammation across both lungs.
The Viruses Behind It
Seven virus families account for the vast majority of viral pneumonia cases: influenza, RSV, rhinoviruses, adenoviruses, human metapneumovirus, parainfluenza viruses, and coronaviruses (including SARS-CoV-2). Which one is most likely to cause trouble depends heavily on the patient’s age.
In children, RSV and rhinoviruses dominate. A large CDC-funded study (the EPIC study) found that among children hospitalized with pneumonia, RSV was detected in 28% of cases and rhinoviruses in 27%. Human metapneumovirus and adenoviruses were next, at 13% and 11% respectively. Influenza caused only about 7% of childhood cases.
The picture flips in adults. Rhinoviruses topped the list at 9%, followed by influenza at 6%, human metapneumovirus at 4%, and RSV at 3%. These percentages reflect detection rates in hospitalized patients, so they represent the more serious end of the spectrum. Many milder cases of viral pneumonia never lead to a hospital visit.
The scale of illness these viruses cause is enormous. In the United States during the 2024-2025 respiratory season alone, COVID-19 was associated with an estimated 290,000 to 450,000 hospitalizations and 34,000 to 53,000 deaths. RSV accounted for another 190,000 to 350,000 hospitalizations and 10,000 to 23,000 deaths in the same period.
How Viruses Reach Your Lungs
Respiratory viruses spread primarily through droplets and aerosols released when an infected person coughs, sneezes, or talks. You can also pick up viruses by touching contaminated surfaces and then touching your nose, mouth, or eyes. But inhaling a virus into your nose or throat is not the same thing as developing pneumonia. Most respiratory infections stay in the upper airways, causing a cold or flu. Pneumonia develops when viruses penetrate deeper, into the small air sacs (alveoli) of the lungs.
This can happen in three ways. The most common route is direct entry: you inhale viral particles deep enough that they reach the lungs, as typically happens with influenza and RSV. In the second pathway, a virus infects the upper airway first and then spreads downward into the lungs over several days, which is how measles sometimes progresses. The third and rarest route is through the bloodstream, where a virus infecting another part of the body travels to the lungs. This is seen with cytomegalovirus (CMV) in people with weakened immune systems.
Once a virus reaches the alveoli, it infects the cells lining the air sacs. Your immune system responds aggressively, sending waves of white blood cells to the area. This immune response, while necessary, causes collateral damage. The walls of the air sacs swell, fluid leaks into spaces that should contain air, and tiny blood vessels in the area become more permeable. The result is the hallmark of pneumonia: impaired gas exchange that makes it harder to get oxygen into your blood. In severe cases, this cascade progresses to widespread lung inflammation, pulmonary edema, and acute respiratory distress syndrome (ARDS).
Incubation Period by Virus
The time between catching a virus and developing symptoms varies considerably. Influenza A has the shortest incubation period, with a median of just 1.4 days. Parainfluenza takes about 2.6 days. RSV averages 4.4 days, and adenovirus is the slowest of the common respiratory viruses at 5.6 days. Keep in mind that these are incubation periods for initial symptoms like fever and cough. Pneumonia itself often develops several days after those first symptoms appear, as the infection works its way deeper into the lungs.
Who Is Most Vulnerable
Age is the single strongest predictor of severe viral pneumonia. The highest hospitalization rates fall at both extremes of life. For RSV, infants under 12 months were hospitalized at a rate of roughly 1,117 per 100,000, while adults 75 and older were hospitalized at about 427 per 100,000. COVID-19 showed a similar pattern, with hospitalization rates of 933 per 100,000 for adults 75 and older and 286 per 100,000 for infants under 6 months.
Among adults who died of viral pneumonia in a large Brazilian hospital study, 78% were over 60. The median age of those who died was 75, compared to 57 for all hospitalized patients. Men who were hospitalized had a higher death rate than women.
Underlying health conditions sharply increase the danger. In that same study, 68% of patients who died had at least one chronic condition, compared to 45% of survivors. The conditions that raised mortality risk the most were:
- HIV/AIDS: more than doubled the risk of dying in the hospital
- Obesity: increased the risk by 87%
- Cancer: increased the risk by 18%
- Diabetes: increased the risk by 18%
- Neurological disorders: increased the risk by about 14%
Chronic lung disease and congestive heart failure were the most commonly seen conditions among hospitalized patients, even though they did not independently predict death as strongly as the conditions above. Anyone with a weakened immune system, whether from disease, medication, or organ transplant, faces elevated risk because their body struggles to contain viral replication before it overwhelms the lungs.
How Viral Pneumonia Differs From Bacterial
Distinguishing viral from bacterial pneumonia matters because the treatments are different. Antibiotics work against bacteria but do nothing for viruses. In practice, telling them apart can be difficult, even for clinicians.
Viral pneumonia tends to produce patchy, diffuse shadows across both lungs on a chest X-ray, while bacterial pneumonia more often appears as a dense white area concentrated in one lobe. But these patterns overlap enough that imaging alone is not reliable. Blood tests offer additional clues. A marker of inflammation called procalcitonin rises sharply during bacterial infections, often exceeding 2 ng/mL within hours, while viral pneumonia tends to keep procalcitonin levels low (often below 0.1 ng/mL). Another common blood marker, C-reactive protein (CRP), also runs higher in bacterial cases but has enough overlap between the two types to make it unreliable on its own. White blood cell counts tend to stay relatively normal in viral infections, while bacterial pneumonia often pushes them above 11,000 per microliter.
In many cases, doctors use a combination of these markers alongside the clinical picture, the patient’s symptoms, and the season (flu season vs. summer, for instance) to guide their judgment.
Secondary Bacterial Infections
One of the most dangerous aspects of viral pneumonia is that it can open the door to a bacterial infection on top of the viral one. The virus damages the lining of the airways and suppresses local immune defenses, creating conditions where bacteria that normally live harmlessly in the nose and throat can invade the lungs.
Secondary bacterial pneumonia complicates an estimated 0.5% to 6% of influenza infections, with the highest rates among patients in intensive care units and those who ultimately die. This is why some people with the flu seem to improve briefly before taking a sharp turn for the worse several days later. That second wave of illness often signals a bacterial superinfection.
Beyond secondary pneumonia, viral respiratory infections have also been linked to bacterial sinus infections, ear infections in children, and in rare cases, meningococcal meningitis following influenza. These complications reinforce why viral pneumonia, even when it starts mild, warrants attention if symptoms worsen or return after an initial improvement.